Mylan: The Market Really, Really, Really Doesn’t Like the Meda Deal

Shares of Mylan ( MYL ) have tumbled nearly 20% after the UK-based pharmaceutical company said it would buy Swedish drug maker Meda for $7.2 billion. Citigroup's Liav Abraham and Nick Nieland explain why they don't like the deal:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.